A Phase I Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Capivasertib Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours.
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Capivasertib (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2021 Planned End Date changed from 29 Apr 2022 to 29 Jul 2022.